CD274 and neoplasm: However, a study of Andrew and Vaibhav [7] assessed PD-L1 as a predictive biomarker across all FDA-approved immune checkpoint inhibitors, analyzing 45 primary studies spanning from 2011 to April 2019; encompassing 15 different tumor types showed that PD-L1 was predictive in only 28.9% of all approvals and was either not predictive (53.3%) or not tested (17.8%) in the remaining cases.